The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

Thu, 11th Mar 2021 20:08

Evgen Pharma PLC - Liverpool-based clinical stage drug development company - Says that after a review of the first 60 patients enrolled, the Data Safety Monitoring Committee for the STAR Covid-19 trial has concluded that there are no concerns regarding patient safety or data quality that would prevent continuation of the trial. Says the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy, it adds.

Chief Executive Officer Huw Jones says: '"We are pleased with the conclusion of the data monitoring committee with regard to safety and data quality in the STAR COVID 19 study. The former conclusion reinforces what we know about the positive safety and tolerability of SFX-01 from previous studies and the latter is yet another testament to the excellent work carried out by Professor James Chalmers and his colleagues at Dundee under challenging circumstances."

Current stock price: 7.95 pence

Year-to-date change: down 22%

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
24 Jun 2016 09:49

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Read more
31 May 2016 09:59

Evgen Pharma Pleased With "Significant Progress" Since AIM Listing

Read more
3 May 2016 07:42

Evgen Pharma Doses First Patients In Phase 2 SFX-01 Trial For Stroke

Read more
2 Mar 2016 09:44

Evgen Pharma Gets Approvals To Begin Phase II SFX-01 Trial

Read more
19 Jan 2016 15:32

CORRECT: DIRECTOR DEALINGS: Evgen Pharma Directors Buy 136,000 Shares

Read more
19 Jan 2016 14:59

Berkeley Group non-exec picks up first shares

(ShareCast News) - First Derivatives non-executive director David Anderson offloaded 5,000 shares in the software and consulting firm at 1,541p each. The sale brought his interest in the company down to 120,000 shares, or 0.5% of the issued share capital. Elsewhere, Berkeley Group non-executive dir

Read more
19 Jan 2016 09:51

DIRECTOR DEALINGS: Evgen Pharma Directors Bought 136,000 Shares

Read more
4 Jan 2016 11:52

Evgen appoints new Chief Medical Officer

(ShareCast News) - Evgen Pharma announced the appointment of a new Chief Medical Officer on Monday. The AIM-listed clinical stage drug development company, focused on the treatment of cancer and neurological conditions, said Dr Hamina Patel would be appointed to the post. Dr Patel was described by

Read more
7 Dec 2015 09:20

Evgen Says "Very Encouraged" By SFX-01 Development In Maiden Results

Read more
26 Nov 2015 09:45

BROKER RATINGS SUMMARY: OneSavings Upped To Buy, Aldermore Cut To Hold

Read more
23 Nov 2015 09:04

Evgen Pharma Buys Licensing Rights For Range Of Compounds In Spain

Read more
21 Oct 2015 11:24

Evgen Pharma Joins AIM With GBP7.0 Million Raised In IPO (ALLIPO)

Read more
9 Sep 2011 16:55

London close: Stocks dive on euro worries

The volatility continued heading into the weekend and stocks were nursing hefty losses at the close of play. The resignation of European Central Bank official Juergen Stark brought the Eurozone crisis into focus. Stark, a German, like many of his compatriots is unhappy about the Bank's policy of b

Read more
9 Sep 2011 12:33

Broker tips: Home Retail, Premier Farnell, Evolution

Singer Capital Markets has slashed its target price for FTSE 250 retailer Home Retail Group by 29%, after the group's first half results showed continued tough trading at Argos and a challenging second quarter for Homebase. "Whilst not as bad as feared the continued weakness of trade at Argos and o

Read more
9 Sep 2011 12:11

Broker snap: Peel Hunt ups target for Evolution after Investec offer

Following Investec's recommended offer for Evolution, Peel Hunt has raised its target price on the investment banking and stockbroking firm from 86p to 100p to reflect the offer price. Investec, the FTSE 100 South African banking titan, announced on Friday morning that it has made a recommended off

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.